Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

AEON Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

IRVINE, CALIF., DEC. 19, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY REPORTED THE GRANTS IN DECEMBER TOTALING 392,158 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY.

AEON BIOPHARMA REPORTS INDUCEMENT GRANTS UNDER NYSE AMERICAN LLC COMPANY GUIDE SECTION 711

- AEON AND DAEWOONG PHARMACEUTICAL HAVE EXECUTED DEFINITIVE DOCUMENTATION TO EXCHANGE $15 MILLION OF NOTES PLUS ACCRUED INTEREST INTO NEW EQUITY, $1.5 MILLION OF NEW NOTES DUE 2030, AND A CASH-EXERCISE WARRANT FOR 8 MILLION SHARES OF COMMON STOCK  - EXCHANGE REMAINS SUBJECT TO SHAREHOLDER APPROVAL - IRVINE, CALIF., DEC. 15, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED THAT THE COMPANY AND DAEWOONG PHARMACEUTICAL (DAEWOONG) HAVE ENTERED INTO A DEFINITIVE AGREEMENT TO EXCHANGE THE COMPANY'S $15 MILLION OF CONVERTIBLE NOTES PLUS ACCRUED INTEREST INTO NEW EQUITY, $1.5 MILLION OF NEW NOTES DUE 2030, AND A CASH-EXERCISE WARRANT FOR 8 MILLION SHARES OF COMMON STOCK, ON THE SAME TERMS AS THE WARRANTS IN THE PRIVATE PLACEMENT FINANCING ANNOUNCED IN NOVEMBER 2025 (THE EXCHANGE).

AEON BIOPHARMA ANNOUNCES EXECUTION OF EXCHANGE AGREEMENT WITH DAEWOONG

-FIRST CLOSING OF PIPE RESULTED IN ~$1.79M IN PROCEEDS - - FDA BPD TYPE 2A MEETING NOW SCHEDULED FOR JANUARY 21, 2026 - IRVINE, CALIF., NOV. 20, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED THE FIRST CLOSING OF ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT (PIPE).

AEON BIOPHARMA ANNOUNCES FIRST CLOSING OF PIPE INVESTMENT AND PROVIDES UPDATE ON FDA TYPE 2A MEETING SCHEDULING

 FDA TYPE 2A MEETING SCHEDULED FOR NOVEMBER 19, 2025, TO REVIEW AEON'S ANALYTICAL DEVELOPMENT PLAN AND INITIAL DATA   POSITIVE BIOSIMILARITY DATA FOR ABP-450 CONFIRMING IDENTICAL AMINO-ACID SEQUENCING AND HIGHLY SIMILAR FUNCTIONAL CHARACTERISTICS SUBMITTED TO FDA AHEAD OF SCHEDULED TYPE 2A MEETING   TWO COMPLEMENTARY FINANCING TRANSACTIONS ANNOUNCED IN NOVEMBER 2025 - $6 MILLION PIPE FINANCING AND A PROPOSED DAEWOONG NOTE EXCHANGE - ARE EXPECTED TO STRENGTHEN AEON'S BALANCE SHEET, REDUCE OUTSTANDING DEBT BY MORE THAN 90%, ACCELERATE THE ABP-450 BIOSIMILAR PROGRAM BY UP TO SIX MONTHS, AND EXTEND CASH RUNWAY INTO THE SECOND QUARTER OF 2026  IRVINE, CALIF., NOV. 14, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING AN ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

AEON BIOPHARMA REPORTS THIRD QUARTER 2025 RESULTS, INCLUDING POSITIVE ABP-450 BIOSIMILARITY DATA AND STRATEGIC POSITIONING FOR CONTINUED GROWTH

-COMBINED TRANSACTIONS WILL STRENGTHEN BALANCE SHEET AND REDUCE OUTSTANDING DEBT BY MORE THAN 90% - - $6 MILLION PIPE FINANCING WITH POTENTIAL FOR OVER $7 MILLION OF ADDITIONAL CAPITAL VIA CASH-EXERCISE WARRANTS - - DAEWOONG HAS ENTERED BINDING TERM SHEET FOR EXCHANGE OF $15 MILLION OF NOTES PLUS ACCRUED INTEREST INTO EQUITY, $1.5 MILLION NEW NOTE DUE 2030 AND 8 MILLION CASH-EXERCISE WARRANTS TOTALING OVER $8M OF POTENTIAL PROCEEDS - - TRANSACTIONS EXPECTED TO SUPPORT UNINTERRUPTED ADVANCEMENT OF AEON'S ABP-450 BIOSIMILAR PROGRAM FOLLOWING POSITIVE ANALYTICAL DATA SUBMITTED TO FDA  IRVINE, CALIF., NOV. 13, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED TWO COMPLEMENTARY TRANSACTIONS TOTALING UP TO ~$22 MILLION IN POTENTIAL PROCEEDS THAT WILL COLLECTIVELY TRANSFORM THE COMPANY'S BALANCE SHEET, ELIMINATE NEARLY ALL OUTSTANDING DEBT, AND PROVIDE CAPITAL TO ACCELERATE PROGRAM EXECUTION AHEAD OF AEON'S UPCOMING FDA TYPE 2A MEETING.

AEON BIOPHARMA ANNOUNCES FUNDRAISE TOTALING UP TO ~$22 MILLION THROUGH PRIVATE PLACEMENT AND PROPOSED EXCHANGE OF DAEWOONG CONVERTIBLE NOTES

- MEETING DATE ALIGNS WITH PRIOR GUIDANCE - - FDA TO REVIEW AEON'S ANALYTICAL DEVELOPMENT PLAN AND INITIAL DATA - IRVINE, CALIF., OCT. 01, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A BIOPHARMACEUTICAL COMPANY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS SCHEDULED A BIOSIMILAR BIOLOGICAL PRODUCT DEVELOPMENT (BPD) TYPE 2A MEETING FOR ABP-450 ON NOVEMBER 19, 2025, IN LINE WITH PRIOR GUIDANCE.

AEON BIOPHARMA ANNOUNCES FDA BPD TYPE 2A MEETING FOR ABP-450 ON NOVEMBER 19

 MULTIPLE NEAR-TERM POTENTIAL MILESTONES, INCLUDING ANTICIPATED COMPLETION OF PRIMARY STRUCTURE ANALYSIS AND SELECT FUNCTIONAL ANALYSES IN 3Q'25   TYPE 2A MEETING WITH THE FDA ANTICIPATED IN 4Q'25  CASH RUNWAY EXPECTED TO SUPPORT OPERATIONS THROUGH FDA MEETING AND REGULATORY FEEDBACK  IRVINE, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING AN ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

AEON BIOPHARMA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

HEXAGON LEVERAGES INDUSTRY-LEADING EXPERTISE IN MEASUREMENT TECHNOLOGIES, AI AND AUTONOMOUS SYSTEMS TO INTRODUCE AN ADVANCED HUMANOID ROBOT TO ACCELERATE NEXT-GENERATION AUTONOMY AEON COMBINES BEST-IN-CLASS LOCOMOTION, SENSOR FUSION, AND AI-BASED SPATIAL INTELLIGENCE TO ADDRESS LABOUR SHORTAGES AND TACKLE INDUSTRIAL USE CASES SCHAEFFLER AND PILATUS WILL PILOT THE HUMANOID ACROSS A VARIETY OF USE CASES AND ENVIRONMENTS STOCKHOLM , JUNE 17, 2025 /PRNEWSWIRE/ --HEXAGON, THE GLOBAL LEADER IN MEASUREMENT TECHNOLOGY, LAUNCHES A HUMANOID ROBOT, AEON, AT ITS FLAGSHIP HEXAGON LIVE GLOBAL EVENT. AEON, LAUNCHED BY HEXAGON'S PREVIOUSLY ANNOUNCED ROBOTICS DIVISION, HAS BEEN SPECIFICALLY DESIGNED TO MEET REAL-WORLD CUSTOMER NEEDS AND ADDRESS LABOUR SHORTAGES.

HEXAGON LAUNCHES AEON, A HUMANOID BUILT FOR INDUSTRY

IRVINE, CALIF., MAY 23, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, TODAY REPORTED THE GRANT IN MAY OF 102,880 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPANY'S BOARD OF DIRECTORS UNDER THE AEON 2025 INDUCEMENT INCENTIVE PLAN, WHICH A GRANT DATE AND VESTING COMMENCEMENT DATE OF MAY 21, 2025.

IRVINE, CALIF., MAY 19, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, TODAY ANNOUNCED THAT ROB BANCROFT, AEON'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT A CORPORATE OVERVIEW AT THE AEGIS CAPITAL CORP. 2025 VIRTUAL CONFERENCE ON WEDNESDAY, MAY 21ST AT 7:00 A.M. PT / 10:00 AM ET.

AEON Biopharma, Inc.

AEON

Price

Financial Reports

No items found.

Press Releases

AEON Biopharma, Inc.

AEON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AEON